The lead author said the study also showed the inavolisib-based therapy "more than doubled the time before their cancer progressed or worsened".

The lead author said the study also showed the inavolisib-based therapy "more than doubled the time before their cancer progressed or worsened".

A new “triple therapy” could provide a lifeline for women with incurable breast cancer by helping them survive the disease ...

A trial has found that the drug is twice as effective as existing treatments at extending the lives of patients with ...

A new three-drug combination could help women with a common form of aggressive breast cancer live longer, research suggests - ...

New breast cancer drug vepdegestrant shows promising results in increasing survival rates for patients with ESR1 mutations.

Dutch authorities say there is currently no evidence that children in the Netherlands were conceived using sperm from a donor ...

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Rare cancer gene TP53 found in 23 out of 67 donor-conceived children * 10 children have already developed cancer, including ...